Citi’s senior analyst Geoff Meacham says investors should reduce exposure to Moderna (MRNA) before the biotech stock comes crashing down in the final quarter of 2026.
Meacham downgraded MRNA this morning to “Sell” and raised his price objective to $80, which nonetheless suggests potential downside of an alarming 60% from current levels.